Compounded BPC-157 in Montana
Check whether compounded BPC-157 can be routed, what restrictions may apply, and what to ask your prescriber or pharmacist.
Read the compounded BPC-157 background guide →About Compounded BPC-157 in Montana
Important: BPC-157 is not currently eligible for compounding by licensed U.S. pharmacies due to FDA restrictions. Quote requests for BPC-157 cannot be fulfilled through Compounding Finder at this time.
Key Questions About BPC-157
Can I get BPC-157 compounded?
Not through Compounding Finder right now. A prescriber and pharmacist still have to decide whether any compounded BPC-157 preparation is legally and clinically appropriate.
Will Compounding Finder send my BPC-157 request to pharmacies?
No. Compounding Finder is not sending BPC-157 quote requests to pharmacies at this time, so we cannot return BPC-157 quotes or prices. If FDA guidance changes, we will revisit.
Source notes: FDA explains that compounded drugs are not FDA-approved finished products and describes 503A compounding around patient-specific prescriptions. See Compounding and the FDA and Section 503A.
Related Medications in Montana
- TB-500 (Thymosin Beta-4) in Montana
- GHK-Cu (Copper Peptide) in Montana
- Thymosin Alpha-1 in Montana
- LL-37 in Montana
- VIP (Vasoactive Intestinal Peptide) in Montana
- 5-Fluorouracil (Topical) in Montana
- Alpha Lipoic Acid (ALA) Injectable in Montana
- Amitriptyline (Topical) in Montana
- Amlexanox in Montana
- Amoxicillin-Clavulanate Flavored Suspension (Veterinary) in Montana
- Anastrozole in Montana
- AOD-9604 in Montana
BPC-157 by City in Montana
Learn more: Compounded BPC-157 — Overview →
Browse all: View All Compounded Medications →
We Do Not Currently Route BPC-157 Quote Requests
BPC-157 is not on the FDA 503A bulk drug substances list. An FDA advisory committee voted in July 2026 to recommend adding it, but FDA has not acted, so US compounding pharmacies have no clear legal pathway to prepare it and Compounding Finder is not sending BPC-157 quote requests to pharmacies. If FDA guidance changes, we will revisit.